Adenoviral and adeno-associated vectors were engineered for capsid display of peptides identified on tumor-activated endothelium, or bispecific antibodies cognate for integrins, selectins, or vessel luminal cell surface receptors [37]–[39]. This evidence concerns the gene CD177 and neoplasm.